source
- Chutes & Ladders—Former Legend CEO lands at K2Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…Fierce Biotech · 1d ago↗ source
- Seven deaths linked to Neurocrine’s Prader-Willi drug Vykat raise safety concernsClinicians have warned that seven patients who received Neurocrine Biosciences' recently approved Prader-Willi syndrome therapy Vykat have died, prompting a new safety alert for the patient communi…